Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15458
Abstract: Therapeutic improvements are needed for patients with acute myeloid leukemia (AML), particularly those who have relapsed or who have treatment‐refractory (R/R) AML or newly diagnosed patients with poor prognostic factors. Alvocidib (DSP‐2033), a potent cyclin‐dependent… read more here.
Keywords: myeloid leukemia; cytarabine daunorubicin; cytarabine mitoxantrone; cytarabine ... See more keywords
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Oncotarget"
DOI: 10.18632/oncotarget.27618
Abstract: A substantial segment of patients with acute myeloid leukemia (AML) will relapse following an initial response to induction therapy or will prove to be primary refractory. High-dose cytarabine and mitoxantrone (HiDAC/MITO) is an established salvage… read more here.
Keywords: high dose; myeloid leukemia; dose cytarabine; cytarabine mitoxantrone ... See more keywords